PROCEPT BioRobotics Corporation
NASDAQ:PRCTMedical - Devices
+$0.19 today
- Market cap
- $1.45B
- Beta
- 0.85
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$1.81
Volume 2.05M
Average 1.46M
PRCT Net Income
Bottom-line profit after all expenses, interest, and taxes.
PROCEPT BioRobotics CorporationNASDAQ: PRCT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$31.64M, compared with -$24.74M a year earlier. Trailing-twelve-month net income was -$102.47M.
Context
- Net income amounted to 31.0% of revenue in FY2025, down 9.7 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of -$95.57M (+0.0%) for the fiscal year ending Dec 2026, a step up from the -4.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$31.64M-6.0% QoQ
- Last fiscal yearDec 2025
- -$95.57M-4.5% YoY
- LTMMar 2026
- -$102.47M-13.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.9% | -35.2% | -7.3 pp |
| 1 year | -4.5% | +0.0% | +4.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (95.57M) USD
- Year-over-year change
- -4.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (95.57M) | -4.5% |
| FY2024 | 2024-12-31 | (91.41M) | +13.7% |
| FY2023 | 2023-12-31 | (105.9M) | -21.5% |
| FY2022 | 2022-12-31 | (87.15M) | -45.6% |
| FY2021 | 2021-12-31 | (59.85M) | — |
Net Income vs competitors
How PRCT compares with its peers on the latest reported figures
- PRCT's LTM Mar 2026 net income of -$102.47M is the lowest of the 5 companies compared; the peer median is -$21.64M.
- Its year-over-year change of -13.6% is the 2nd highest of 4, against a peer median of -21.8%.
- Net income amounts to 31.8% of revenue for PRCT, versus a peer median of 56.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$10.03M | +48.1% | — | 20.7% | |
| LTM Mar 2026 | -$14.21M | -21.8% | — | 13535.2% | |
| LTM Mar 2026 | -$29.07M | -39.8% | — | 71.6% | |
FOCLEDAP TMS S.A. American Depositary Shares | LTM Mar 2026 | -$30.77M | — | — | 41.5% |
| LTM Mar 2026 | -$102.47M | -13.6% | — | 31.8% | |
| Peer median (excluding PRCT) | -$21.64M | -21.8% | — | 56.5% | |
Competitors are the stored peer set for PRCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.47M | 75.01M | 136.19M | 224.5M | 308.05M |
| Cost of Revenue | 18.61M | 37.93M | 65.14M | 87.4M | 111.83M |
| Gross Profit | 15.87M | 37.09M | 71.05M | 137.1M | 196.23M |
| Gross Margin | 46.0% | 49.4% | 52.2% | 61.1% | 63.7% |
| Research & Development | 18.99M | 28.98M | 48.45M | 62.3M | 71.28M |
| Selling, General & Admin | 51.04M | 88.83M | 131.77M | 171.42M | 228.81M |
| Operating Expenses | 70.03M | 117.81M | 180.22M | 233.71M | 300.09M |
| Depreciation & Amortization | 3.32M | 2.84M | 3.81M | 5.23M | 6.39M |
| EBITDA | (50.72M) | (79.13M) | (98.1M) | (82M) | (85.41M) |
| EBITDA Margin | -147.1% | -105.5% | -72.0% | -36.5% | -27.7% |
| Operating Income | (54.16M) | (80.72M) | (109.17M) | (96.61M) | (103.86M) |
| Operating Margin | -157.1% | -107.6% | -80.2% | -43.0% | -33.7% |
| Interest Income | 76K | 2.5M | 7.55M | 10.9M | 12.22M |
| Interest Expense | 5.81M | 5.18M | 4M | 4.18M | 3.59M |
| Other Income / Expenses | (5.69M) | (6.43M) | 3.27M | 5.2M | 8.48M |
| Income Before Tax | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.38M) |
| Pre-Tax Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 190K |
| Net Income | (59.85M) | (87.15M) | (105.9M) | (91.41M) | (95.57M) |
| Net Margin | -173.6% | -116.2% | -77.8% | -40.7% | -31.0% |
| EPS (Basic) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| EPS (Diluted) | (1.37) | (1.96) | (2.24) | (1.75) | (1.72) |
| Weighted Avg Shares | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
| Weighted Avg Shares (Diluted) | 43.7M | 44.4M | 47.26M | 52.13M | 55.54M |
PROCEPT BioRobotics Corporation
NASDAQ:PRCT
Intrinsic Alpha fair value
Locked
Current Price
$25.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.